Over the past month, web traffic data from investment research platforms show that searches for United Parcel Service, Inc. rose by 65% compared with the previous quarter, driven by concerns over its recent operating performance and strategic shifts. Daily active user inquiries peaked following the company’s announcement of a new healthcare-focused pricing structure, indicating heightened scrutiny of its efforts to diversify beyond e-commerce volumes. Institutional ownership data also flagged several funds adding to their positions last week, suggesting some investors view current levels as an entry point.

From 2022 through the first nine months of 2025, UPS’s average daily package volume declined from 24.3 million to 19.97 million, while total revenue fell from $100.34 billion to $64.18 billion over the same period. Although average revenue per package climbed from $13.38 to $14.46 thanks to targeted fee increases and a reduced dependence on large–volume, lower-margin customers, this tactic only partially offset the 34% drop in overall shipments. Operating margins contracted from 13.8% in 2022 to 6.8% in the first nine months of 2025, reflecting higher labor costs under the Teamsters agreement and investments in automation.

In November, the Federal Aviation Administration grounded all of UPS’s MD-11 freighter aircraft—approximately 9% of its air fleet—following a fatal incident in Kentucky. The grounding occurred during peak holiday season, forcing the company to reroute cargo through older wide-body jets, third-party carriers and ground transport. Internal logistics reports estimate the incident shaved 1.2 percentage points off fourth-quarter operating margin, and management has warned that rerouting costs could persist into the first half of 2026 as capacity is rebuilt.

Consensus estimates project a 3% revenue decline for full-year 2025, with adjusted earnings per share down a similar amount due to one-time charges and fleet disruptions. For 2026, analysts anticipate revenue to stabilize near current levels as margin-enhancing initiatives—such as higher-margin healthcare shipments and further automation—begin to take effect. Earnings per share are forecast to rebound by approximately 7%, though this assumes successful resolution of the MD-11 capacity shortfall and no further labor-cost escalations. Investors will closely watch the January earnings release for signs of margin recovery and volume stabilization.